Stifel Financial
TCRX icon

Stifel Financial’s TScan Therapeutics TCRX Stock Holding History

Stifel Financial’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.1K Sell
69,400
-3,000
-4% -$3.21K ﹤0.01% 3561
2025
Q4 		$72.4K Sell
72,400
-25,000
-26% -$36.2K ﹤0.01% 3510
2025
Q3 		$177K Sell
97,400
-18,541
-16% -$32.8K ﹤0.01% 3373
2025
Q2 		$168K Sell
115,941
-511
-0.4% -$738 ﹤0.01% 3290
2025
Q1 		$161K Buy
116,452
+6,752
+6% +$14.6K ﹤0.01% 3222
2024
Q4 		$333K Buy
109,700
+10,567
+11% +$47.9K ﹤0.01% 2908
2024
Q3 		$494K Buy
99,133
+3,733
+4% +$22.5K ﹤0.01% 2689
2024
Q2 		$558K Sell
95,400
-6,000
-6% -$47.3K ﹤0.01% 2555
2024
Q1 		$805K Sell
101,400
-19,000
-16% -$120K ﹤0.01% 2319
2023
Q4 		$702K Buy
120,400
+3,500
+3% +$16K ﹤0.01% 2368
2023
Q3 		$299K Buy
116,900
+17,900
+18% +$41.8K ﹤0.01% 2793
2023
Q2 		$248K Buy
+99,000
New +$266K ﹤0.01% 2934

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Stifel Financial's TCRX Position: Q1 2026 in Review

Stifel Financial reduced its TScan Therapeutics (TCRX) stake by 4.1% in Q1 2026, selling an estimated $3.21K and leaving 69,400 shares worth $70.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Stifel Financial first reported a position in TCRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $805K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Stifel Financial held 69,400 shares of TScan Therapeutics worth $70.1K as of Q1 2026.
  • Stifel Financial sold 3,000 TScan Therapeutics shares in Q1 2026, an estimated $3.21K.
  • TScan Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q1 2026, its #3561 holding.
  • Stifel Financial first reported a position in TScan Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Stifel Financial's TScan Therapeutics position peaked at $805K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Stifel Financial's 13F filing for Q1 2026, filed 12 May 2026.